Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer

doi:10.4251/wjgo.v10.i12.505

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9395)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

522

WORD

200

HTML

4063

Figures (1-1)

313

Tables (1-5)

263

Sum=5361

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

571

Download

1213

Sum=1784

Publishing Process of This Article

Item

Count

Browse

961

Download

1289

Sum=2250

Dec 15, 2018 (publication date) through Dec 20, 2024

Times Cited of This Article

Times Cited (26)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastrointest Oncol. Dec 15, 2018; 10(12): 505-515
Published online Dec 15, 2018. doi: 10.4251/wjgo.v10.i12.505

Table 5 Comparison with previous studies focused on FOLFIRINOX as a second-line therapy

Study characteristics			Patients characteristics				Treatment outcomes				Grade ≥ 3 AE (%)
Author (yr)	Type	Dose modification	Patients, n	Age, median (range)	ECOG	Cancer status (%)	ORR, %	DCR, %	PFS, mo	OS, mo	NP	Febrile NP	Fatigue	Nausea	Diarrhoea
Assaf et al[29] 2011	Retro	Standard	27	63 (45-83)	1-3	MPC (100)	18.5	62.9	3	8.5	56	3.7	NA	11	11
Lee et al[30] 2013	Retro	Standard	18	57 (44-68)	0-1	MPC (88.9)	27.8	55.6	2.8	8.4	38.9	11.1	NA	38.9	0
Lee et al[30] 2013	Retro	Standard	18	57 (44-68)	0-1	LAPC (11.1)	27.8	55.6	2.8	8.4	38.9	11.1	NA	38.9	0
Kobayashi et al[27] 2017	II	Irinotecan 56% or 67%	18	63 (46-68)	0-1	MPC (100)	22.2	61.1	2.8	9.8	66.7	5.6	NA	0	0
Present study	II	Irinotecan 67%	48	64 (40-79)	0-2	MPC (79.2)	All: 18.8	All: 62.5	All: 5.8	All: 9.0	64.6	16.7	16.7	0	2.1
		Oxaliplatin 71%				LAPC (20.8)	MPC: 23.7	MPC: 57.9	MPC: 5.4	MPC: 8.4
		Oxaliplatin 71%				LAPC (20.8)	LAPC: 0.0	LAPC: 80.0	LAPC: 8.8	LAPC: 12.5

AE: Adverse event; ECOG: Eastern Cooperative Oncology Group performance status; ORR: Objective response rate; DCR: Disease control rate; PFS: Progression-free survival; OS: Overall survival; NP: Neutropenia; WHO-PS,: World Health Organization performance status; II: Phase II study; Retro: Retrospective study; MPC: Metastatic pancreatic cancer; LAPC: Locally advanced pancreatic cancer; NA: Not available.

Citation: Chung MJ, Kang H, Kim HG, Hyun JJ, Lee JK, Lee KH, Noh MH, Kang DH, Lee SH, Bang S, Pancreatobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer. Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer. World J Gastrointest Oncol 2018; 10(12): 505-515
URL: https://www.wjgnet.com/1948-5204/full/v10/i12/505.htm
DOI: https://dx.doi.org/10.4251/wjgo.v10.i12.505